Evaluation of retinotoxicity of COVID‐19 treatment: Hydroxychloroquine and lopinavir/ritonavir

Despite no established treatment for COVID‐19, hydroxychloroquine (HCQ) and lopinavir/ritonavir are being used. We read with interest the recent article of Chong et al.1

Saved in:
Bibliographic Details
Published in:Journal of Medical Virology 2021-02, Vol.93 (2), p.644-646
Main Authors: Burgos‐Blasco, Barbara, Güemes‐Villahoz, Noemi, Vidal‐Villegas, Beatriz, Donate‐Lopez, Juan, Garcia‐Feijoo, Julian
Format: Article
Language:English
Subjects:
Antimalarials - adverse effects
Antiretroviral drugs
Antiviral Agents - adverse effects
Antiviral drugs
COVID-19
COVID-19 - complications
COVID-19 - drug therapy
Cross-Sectional Studies
Drug Combinations
Female
Humans
Hydroxychloroquine
Hydroxychloroquine - adverse effects
Letter to the Editor
Lopinavir
Lopinavir - adverse effects
Male
Middle Aged
Optical Imaging
Retina - diagnostic imaging
Retina - drug effects
Retina - pathology
Retina - virology
Ritonavir
Ritonavir - adverse effects
Tomography, Optical Coherence
Virology
Citations: Items that this one cites
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite no established treatment for COVID‐19, hydroxychloroquine (HCQ) and lopinavir/ritonavir are being used. We read with interest the recent article of Chong et al.1
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.26420